Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Scientists show that endothelial cells give rise to blood stem cells

Scientists show that endothelial cells give rise to blood stem cells

Men who survive childhood leukemia have lower bone mineral density

Men who survive childhood leukemia have lower bone mineral density

FDA accepts Zevalin supplemental biologics license application

FDA accepts Zevalin supplemental biologics license application

Researchers discover genomic causes of acute lymphoblastic leukemia relapse

Researchers discover genomic causes of acute lymphoblastic leukemia relapse

Scientists develop peptide that converts Bcl-2 protein from a cancer cell's friend to a foe

Scientists develop peptide that converts Bcl-2 protein from a cancer cell's friend to a foe

Declines in cancer incidence and death rates across U.S.

Declines in cancer incidence and death rates across U.S.

Discovery of novel drug target for chronic lymphocytic leukemia

Discovery of novel drug target for chronic lymphocytic leukemia

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

NCI sponsors Canadian cold/flu remedy trial in leukemia patients

NCI sponsors Canadian cold/flu remedy trial in leukemia patients

COLD-FX remedy undergoes NCI-sponsored trial in leukemia patients

COLD-FX remedy undergoes NCI-sponsored trial in leukemia patients

'Intelligent' cancer drug development boosts success rates

'Intelligent' cancer drug development boosts success rates

Previously unknown regulatory step during HIV replication provides potential new target for HIV/AIDS therapy

Previously unknown regulatory step during HIV replication provides potential new target for HIV/AIDS therapy

Potential new therapeutic targets for rejuvenating the aged immune system

Potential new therapeutic targets for rejuvenating the aged immune system

Strong relationship found between allergies and cancer in environmentally exposed tissues

Strong relationship found between allergies and cancer in environmentally exposed tissues

Terminally ill teenager wins the right to die with dignity

Terminally ill teenager wins the right to die with dignity

Researchers discover metabolic deficiency in pancreatic cancer

Researchers discover metabolic deficiency in pancreatic cancer

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Novel concept in chronic lymphoid leukemia treatment

Novel concept in chronic lymphoid leukemia treatment

Scientists sequence genome of a cancer patient

Scientists sequence genome of a cancer patient

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.